Clinical trials: Intravenous Therapy
Catheterization
Effect of Thermomechanical Stimulation Device and Virtual Reality Glasses During Peripheral Intravenous Catheterization
The study was conducted as a randomized controlled experimental study to determine the effect of Thermomechanical Stimulation Device (Buzzy®) and Virtual Reality Goggles (VRG) applied during peripheral intravenous catheterization…
- Trial name
- NCT05422287
- Testing
- Virtual Reality Glasses, Thermomechanical Stimulation Device
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Ankara Yildirim Beyazıt University
Lung Squamous Cell Carcinoma
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
- Trial name
- NCT05782764
- Testing
- To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xuzhou Medical University
Head and Neck Cancer
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin and radiation therapy in patients with locally advanced head and neck cancer.
- Trial name
- NCT01384799
- Testing
- CUDC-101, Cisplatin, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Curis, Inc.
TTR-mediated Amyloidosis
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT01617967
- Testing
- Patisiran
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 29 people
- Sponsor
- Alnylam Pharmaceuticals
Phlebitis
Use of Chamomilla Recutita in Phlebitis
To verify the efficacy of topical applications of Chamomilla recutita infusion for phlebitis treatment, before dose response curve study and pilot study.
- Trial name
- NCT00989599
- Testing
- compress of Chamomilla recutita infusion, compress of lukewarm water
- Where
- Brazil
- Volunteers
- 123 people
- Sponsor
- University of Sao Paulo
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
- Trial name
- NCT00001499
- Testing
- paclitaxel, cisplatin, chest radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Sclerosis
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
This study compared the efficacy of different dosages of long-term iloprost treatment on Raynaud's phenomenon, ulcer healing, skin thickening, and progression of internal organ sclerosis in systemic sclerosis (SSc). Methods.
- Trial name
- ILODOSE (NCT00622687)
- Testing
- iloprost, iloprost low dose, iloprost therapy up to 2 ng/kg x min
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis
Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
The purpose of this study was to assess the pharmacokinetics, safety, and tolerability of a single intravenous dose of ceftolozane/tazobactam (MK-7625A) in pediatric participants.
- Trial name
- NCT02266706
- Testing
- Ceftolozane/Tazobactam 1000/500 mg, Ceftolozane/Tazobactam 30/15 mg/kg, Ceftolozane/Tazobactam 20/10 mg/kg
- Volunteers
- 43 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Ischemic Stroke
Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry
The clinical and radiological data of patients with an acute ischemic stroke treated with intravenous thrombolysis (IVT) or intraarterial thrombolysis (IAT) in a Swiss stroke unit are assessed in a Swiss Multicenter Thrombolysis…
- Trial name
- SWISS (NCT00811538)
- Testing
- Intravenous Thrombolysis, Intraarterial Thrombolysis
- Where
- Switzerland
- Volunteers
- 1,476 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Post Operative Bowel Dysfunction
Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus
Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.
- Trial name
- NCT00387309
- Testing
- Methylnaltrexone (MOA-728)
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 495 people
- Sponsor
- Bausch Health Americas, Inc.
Traumatic Brain Injury
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for TBI
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of traumatic brain injury
- Trial name
- NCT05018832
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Where
- Antigua and Barbuda
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Ischemic Stroke
Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke
Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) has been the only proven therapy for acute ischemic stroke (AIS) for almost 20 years.
- Trial name
- SWIFT DIRECT (NCT03192332)
- Testing
- Stent-retriever thrombectomy with revascularization device of the Solitaire™ type, Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)
- Where
- 48 sites in Austria, Canada and 6 more
- Volunteers
- 410 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Huntington Disease
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
This is a dose escalation and expansion clinical study to evaluate the safety, tolerability, PK profile and preliminary efficacy of ER2001 Injection vs. placebo in subjects with definitive diagnosis of early manifest HD.
- Trial name
- NCT07339514
- Testing
- ER2001 intravenous injection
- Where
- 3 sites in China
- Volunteers
- 27 people
- Sponsor
- ExoRNA Bioscience
Staphylococcal Infections, Osteomyelitis
Ceftriaxone as Home IV for Staph Infections
Patients who are admitted to hospital with serious infections, such as those in bone, joints or spine, require a long course of intravenous (IV) antibiotics.
- Conditions
- Staphylococcal Infections, Osteomyelitis, CNS Infection, Septic Arthritis
- Trial name
- NCT04141787
- Testing
- Ceftriaxone, Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)
- Where
- 2 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Vancouver Island Health Authority
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
Anaemia in Ovarian Carcinoma
Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer
Cancer related anemia (CRA) is a common sign occurring in more than 30% of patients at diagnosis, prior to initiation of antineoplastic therapy.
- Trial name
- NCT06248749
- Testing
- IV iron
- Where
- 2 sites in Canada
- Volunteers
- 200 people
- Sponsor
- University of Saskatchewan
Cirrhosis, Ascites Hepatic
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
- Trial name
- NCT03107091
- Testing
- Terlipressin acetate continuous infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- BioVie Inc.
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Symptomatic Decompensated Congestive Heart Failure, Congestive Heart Failure in Acute Coronary Syndrome
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.
The purpose of this study is to compare the hemodynamic (blood flow) and clinical effects of the study drug, Natrecor (nesiritide, a recombinant form of the natural human peptide normally secreted by the heart in response to…
- Trial name
- NCT00270374
- Testing
- nesiritide
- Volunteers
- 498 people
- Sponsor
- Scios, Inc.
Acute Ischemic Stroke
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke
The clinical study with UMC119-06 is designed to investigate the safety in patients with acute ischemic stroke ("AIS"). This will be a dose escalation, open-label, single-center study in adult with acute ischemic stroke.
- Trial name
- NCT04097652
- Testing
- UMC119-06
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Meridigen Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.